Abstract: Objective To evaluate the monitoring and evaluation function of liver stiffness measurement (LSM) changes in antiviral therapy for patients with chronic hepatitis B (CHB) cirrhosis.Methods Between February 2015 and September 2019, 256 CHB patients met the inclusion criteria. All the patients included in the study received oral entecavir (0.5 mg/d) and telofovir (300 mg/d) for 2 years. Patients were included in the monitoring index at the time of study, and were monitored every six months until the end of antiviral therapy or liver-related events (LRE) occurred. The time nodes at the start of therapy and at each monitoring were Q0, Q1, Q2, Q3 and Q4. Measurement data are expressed by (±s) and compared by t test. The counting data are expressed in (%) and compared by chi-square test.Results LRE was found in 28 of 256 patients with CHB cirrhosis, including 16 cases of decompensated cirrhosis, 8 cases of liver cancer and 4 cases of death. Patients without LRE are defined as LRE-free group and patients with LRE are defined as LRE group. Age, platelet, albumin, prothrombin time (PTA) and international normalized ratio (INR) in the two groups are significant (P<0.05). There was a significant difference in LSM changes between LRE group and non-LRE group after half a year of antiviral therapy (P<0.05). LRE group Q0, Q1, Q2 and Q3 LSM were 18.6±7.7, 19.4±10.8 , 19.0±12.3 and (19.1±15.2) kPa respectively, while no LRE group Q0, Q1, Q2, Q3 and Q4 LSM were 17.9±6.5, 13.8±7.4,12.3±6.6, 11.1±5.2 and (10.8±5.3) kPa, respectively.Conclusion Changes in LSM during antiviral therapy for CHB cirrhosis patients can help judge the disease condition and have certain monitoring and evaluation value.

Key words: Chronic hepatitis B, Decompensated cirrhosis, Liver stiffness measurement, Liver related events